Answer
Tarceva (erlotinib) is indicated as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations.
Sources for this answer
- Tarceva 25 mg, 100 mg & 150 mg Film-coated TabletsRoche Products Limited · emc · SmPC §4.1 Therapeutic Indications · Version 11Document updated
Sources checked